Levetiracetam ( DrugBank: Levetiracetam )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
4	原発性側索硬化症	1
6	パーキンソン病	6
13	多発性硬化症／視神経脊髄炎	5
307	カナバン病	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00324454 (ClinicalTrials.gov)	May 2006	9/5/2006	Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease	A Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease	Motor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy	Biological: Levetiracetam	Duke University	UCB Pharma	Completed	18 Years	N/A	Both	20	Phase 2	United States

4. 原発性側索硬化症

臨床試験数 : 5 / 薬物数 : 13 - (DrugBank : 6) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 25

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00324454 (ClinicalTrials.gov)	May 2006	9/5/2006	Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease	A Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease	Motor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy	Biological: Levetiracetam	Duke University	UCB Pharma	Completed	18 Years	N/A	Both	20	Phase 2	United States

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643327 (ClinicalTrials.gov)	February 9, 2021	18/11/2020	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study	Parkinson Disease;Mild Cognitive Impairment;Memory Impairment	Drug: Levetiracetam;Drug: Placebo	The University of Queensland	Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's Hospital;Queensland University of Technology	Recruiting	N/A	N/A	All	28	Phase 2	Australia
2	NCT00584025 (ClinicalTrials.gov)	December 2007	21/12/2007	Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease		Parkinson's Disease	Drug: levetiracetam;Drug: Placebo	University of South Florida	NULL	Withdrawn	30 Years	80 Years	All	0	Phase 4	United States
3	NCT00291733 (ClinicalTrials.gov)	May 2006	14/2/2006	Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease	Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial	Levodopa Induced Dyskinesia	Drug: Levetiracetam;Drug: Placebo	1st Hospital of Social Security Services	UCB Pharma	Active, not recruiting	30 Years	80 Years	Both	50	Phase 2	Greece
4	NCT00307450 (ClinicalTrials.gov)	March 2006	27/3/2006	Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease	Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study	Parkinson's Disease	Drug: Levetiracetam	Technische Universität Dresden	UCB GmbH, Huettenstrasse 205, 50170 Kerpen, Germany	Completed	30 Years	80 Years	Both	34	Phase 4	Germany
5	NCT00076674 (ClinicalTrials.gov)	January 2004	28/1/2004	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Dyskinesias;Parkinson Disease	Drug: Intravenous Levodopa	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	40	Phase 2	United States
6	NCT00160576 (ClinicalTrials.gov)	July 2003	8/9/2005	Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias	A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease	Idiopathic Parkinson Disease	Drug: Levetiracetam	UCB Pharma	NULL	Completed	30 Years	N/A	Both	30	Phase 2	NULL

先頭へ

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-005414-40-IT (EUCTR)	21/12/2007	28/11/2007	Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND	Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND	Patients with an established and stable Multiple Sclerosis (according to Poser criteria). MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: KEPPRA INN or Proposed INN: Levetiracetam	AZIENDA SANITARIA N. 3 GENOVESE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
2	NCT00423527 (ClinicalTrials.gov)	January 2007	16/1/2007	Levetiracetam in Central Pain in Multiple Sclerosis(MS)	Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis	Multiple Sclerosis	Drug: levetiracetam	Odense University Hospital	NULL	Completed	18 Years	N/A	Both	30	Phase 4	Denmark
3	EUCTR2006-000397-71-DK (EUCTR)	16/05/2006	02/05/2006	Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis	Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis		Trade Name: Keppra Product Name: Levetiracetam Product Code: ucb L059	Søren H. Sindrup, Department of Neurology, Odense University Hospital	NULL	Not Recruiting			Female: yes Male: yes	30		Denmark
4	EUCTR2005-003903-35-GB (EUCTR)	19/01/2006	19/12/2005	: The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis	: The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis	Multiple Sclerosis	Trade Name: Keppra 250mg INN or Proposed INN: Levetiracetam Trade Name: Keppra 500mg Product Name: Keppra ®	Newcastle-upon-Tyne Hospitals NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
5	EUCTR2005-001776-13-DE (EUCTR)	05/08/2005	26/09/2006	Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study	Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study	Multiple Sclerosis	Product Name: Levetiracetam	Organisation name was not entered	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24		Germany

先頭へ

307. カナバン病

臨床試験数 : 6 / 薬物数 : 11 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04833907 (ClinicalTrials.gov)	April 1, 2021	24/3/2021	rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease	Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan Disease	Canavan Disease	Drug: rAAV-Olig001-ASPA;Drug: Levetiracetam;Drug: Prednisone	Myrtelle Inc.	NULL	Active, not recruiting	3 Months	60 Months	All	24	Phase 1/Phase 2	United States

先頭へ